Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme

This on-demand programme, Malaysia In Focus - Reverse Cardiac Remodelling Educational Programme, has been developed to further education among practicing cardiologists to ensure understanding of the latest developments in reverse cardiac remodelling in heart failure, how emerging data relates to current practice in Malaysia, and is intended to support the application of current understanding of treatment strategies for heart failure, and the role of cardiac remodelling, biomarkers, and provide a review of trials and latest data..

The programme brings together a leading international faculty from Malaysian, US, UK, and Italy, for a seven-part series.

Target Audience

Cardiologists, heart failure specialists, allied health professionals, and GPs with a specialist interest in heart failure.

Learning Objectives

  1. Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  2. List the main clinical implications of cardiac remodelling.
  3. Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  4. Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  5. Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  6. Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.


This programme is endorsed by the National Heart Association to promote quality cardiovascular care through education.


This programme is supported by an unrestricted educational grant from Novartis. Novartis had no involvement in the organisation of the programme.


In compliance with Malaysian Medical Association (MMA) guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations.

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CPD activities.

This programme is supported by an unrestricted educational grant from Novartis. The scientific programme has not been influenced in any way by the sponsor.


Dato’ Dr David Chew 

  • No conflicts of interest to declare pertaining to this programme.

Dr James Januzzi 

  • Grant support from Novartis Pharmaceuticals, Applied Therapeutics, and Innolife
  • Consulting income from Abbott Diagnostics, Janssen, Novartis, Quidel and Roche Diagnostics
  • Clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, CVRx, Janssen, MyoKardia, and Takeda
  • Trustee, American College of Cardiology

Dr Akshay Desai

  • Received consulting fees from Abbott, Alnylam, AstraZeneca, Biofourmis, Boston Scientific, Boehringer-Ingelheim, DalCor Pharma,  Merck, Novartis, Relypsa, Regeneron and Research Grants from AstraZeneca, Alnylam, and Novartis

Prof Andrew Coats

  • No conflicts of interest to declare pertaining to this programme.

Dr Michele Senni

  • Financial interest for consultancy with: Novartis, Merck, Bayer, Vifor Pharma, Abbott, Boehringer Ingelheim, Astra-Zeneca, Bioventrix, Servier

Dr Pardeep Jhund

  • No conflicts of interest to declare pertaining to this programme.


Radcliffe Education requires contributors to our CME/CPD programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

This programme ‘Malaysia In Focus – Reverse Cardiac Remodelling’ is accredited by the Malaysian Medical Association (MMA)  for 1 hour of external CPD credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity.


There is no fee for taking part in this online learning activity.

Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Course summary
Available credit: 
  • 1.00 Malaysian Medical Association (MMA)
Course opens: 
Course expires: 

Program outline

Part 1: Recognising and Treating Cardiac Remodelling in Heart Failure

Part 2: The Clinical Implications of Cardiac Remodelling in Heart Failure

Part 3: Relationship of Cardiac Biomarkers

Part 4: Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities

Part 5: ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putative Placebo Analysis

Part 6: Overview of the Evidence

Part 7: Angiotensin Receptor Neprilysin Inhibitors – Renal Safety and Efficacy

This programme was developed for online administration only.

Faculty Biographies

Dato’ Dr David Chew, Cardiac Vascular Sentral Kuala Lumpur, Malaysia

Dato' Dr David Chew Soon Ping is a Consultant Cardiologist at Cardiac Vascular Sentral  Kuala Lumpur (CVSKL) in Malaysia.

He is a Fellow of The Royal College of Physicians (FRCP), London, and a Bachelor of Medicine, and Bachelor of Surgery (MBBS), University of Malaya. Dr Chew is published widely in leading international peer-reviewed journals on the subject of heart failure, and is a member of several societies and professional bodies, including the National Heart Association of Malaysia (NHAM).

 Dr James Januzzi, Harvard Medical School, Cambridge, US

Dr James Januzzi is an Associate Professor of Medicine at Harvard Medical School and Director of the Cardiac Intensive Care Unit at Massachusetts General Hospital. He has vast experience as a teacher and educator, and leads a research programme with specific focus on cardiac biomarker testing.

Dr Januzzi was the top-ranked graduate in his class at New York Medical College. He completed an internship and residency at Brigham and Women’s Hospital prior to performing a clinical and research fellowship in cardiovascular medicine at the Massachusetts General Hospital, where he also completed a fellowship in cardiac ultrasound. He speaks widely on the topic of biomarker testing in heart disease and treatment of heart failure.  He has served as the Cardiology Consultant to the Boston Red Sox since 2005.

Dr Akshay Desai, Brigham and Women’s Hospital, Boston, US

Dr Akshay Desai is a cardiovascular medicine specialist and the Director of the Cardiomyopathy and Heart Failure Program at Brigham and Women’s Hospital. Dr Desai’s research focuses on improving care and outcomes for HF patients, as well as strategies to reduce heart failure readmissions.

Dr Desai received his medical degree from HMS. He completed an internal medicine residency as well as fellowships in cardiovascular medicine, vascular medicine and advanced heart disease at BWH. He is board certified in and cardiovascular disease, as well as advanced heart failure and transplant cardiology. His clinical interests include advanced heart failure, cardiomyopathies (myocarditis, amyloidosis, sarcoidosis), congenital heart disease and cardiac transplantation. His research has received support from the American College of Cardiology and the National Heart, Lung and Blood Institute.

Prof Andrew Coats, President, Heart Failure Association of the ESC

Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.

Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).

Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.

Prof Coats research interests are chronic heart failure, hypertension, and organizational behaviour. Professor Coats has an MBA from London Business School, is a Diplomate and Fellow of the Australian Institute of Company Directors and member of the UK Institute of Directors.

Dr Michele Senni, ASST Papa Giovanni XXIII, Bergamo, IT

 Dr Michele Senni served from 2004 to 2013 as Head of General Medicine 2 Cardiovascular Hospital of Bergamo. From 2009 to 2010 he was Chairman of the National Association of Cardiologists and Hospital Doctors (ANMCO). Today he is Director of Cardiology 1. He serves on the advisory and editorial boards of major international cardiology journals. He has participated as a speaker at more than 100 international conferences. He is also the author of almost 200 articles and 20 chapters in national and international journals. He has served as PI of leading international trials.

 Dr Pardeep Jhund, Department of Cardiovascular and Medical Sciences, University of Glasgow, UK

 Dr Pardeep Jhund is a clinical and academic cardiologist. He has extensive experience of the design and conduct of clinical trials and endpoint committees. His academic interests focus on clinical trials and the epidemiology of cardiovascular disease. Dr Jhund has published over 70 paper in leading cardiovascular journals. He also teaches on educational courses on clinical trials methods around the world.

This programme accredited by the Malaysian Medical Association (MMA) for 1 external CPD credit. Once the course is completed, there are instructions on how to receive your credit.

Available Credit

  • 1.00 Malaysian Medical Association (MMA)
Please login or register to take this course.